Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | CES1 | P23141 | 4/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9404082 | 0.98 | MAPT (0.65) | MAPTRXFP1HDAC1HDAC2ALOX5 | |
| SCHEMBL9764517 | 0.98 | MAPT (0.65) | MAPTRXFP1HDAC1HDAC2ALOX5 | |
| SCHEMBL29048467 | 0.98 | MAPT (0.65) | MAPTRXFP1HDAC1HDAC2ALOX5 | |
| SCHEMBL8662111 | 0.98 | MAPT (0.65) | MAPTRXFP1HDAC1HDAC2ALOX5 | |
| SCHEMBL9219599 | 0.98 | MAPT (0.65) | MAPTRXFP1HDAC1HDAC2ALOX5 | |
| SCHEMBL9404041 | 0.98 | MAPT (0.65) | MAPTRXFP1HDAC1HDAC2ALOX5 | |
| SCHEMBL5966475 | 0.98 | MAPT (0.65) | MAPTRXFP1HDAC1HDAC2ALOX5 | |
| Bromide SCHEMBL28931279 | 0.98 | MAPT (0.59) | MAPTRXFP1HDAC1HDAC2ALOX5 | |
| SCHEMBL20717644 | 0.98 | MAPT (0.65) | MAPTRXFP1HDAC1HDAC2ALOX5 | |
| Water SCHEMBL27364393 | 0.98 | MAPT (0.59) | MAPTRXFP1HDAC1HDAC2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 564 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113571640-B | Perovskite solar cell containing superimposed composite transmission layer and preparation method thereof | 杭州纤纳光电科技有限公司 | 2024-06-25 | — | — | CN | claimed |
| CN-118119245-A | Preparation method of perovskite solar cell | 衢州纤纳新能源科技有限公司 | 2024-05-31 | — | — | CN | claimed |
| WO-2024051975-A1 | NOVEL DERIVATIVES OF GLYCEROL | SYMRISE AG (DE) | 2024-03-14 | — | — | WO | claimed |
| CN-113745366-B | Perovskite and crystalline silicon three-junction laminated solar cell and preparation method thereof | 杭州纤纳光电科技有限公司 | 2024-03-12 | — | — | CN | claimed |
| CN-114583059-B | Perovskite solar cell with bias electrode | 华碧光能科技(苏州)有限公司 | 2024-02-13 | — | — | CN | claimed |
| WO-2022128052-A1 | MEDICAMENT FOR FIGHTING INFLAMMATORY CONDITIONS OF HUMAN SKIN | SYMRISE AG (DE) | 2022-06-23 | — | — | WO | claimed |
| WO-2022128054-A1 | MEDICAMENT FOR FIGHTING INFLAMMATORY CONDITIONS OF HUMAN SKIN (IV) | SYMRISE AG (DE) | 2022-06-23 | — | — | WO | claimed |
| CN-114583059-A | Perovskite solar cell with bias electrode | 华碧新能源技术研究(苏州)有限公司 | 2022-06-03 | — | — | CN | claimed |
| US-20220165361-A1 | METHODS OF DIAGNOSING DISEASE | 4D Pharma Cork Limited (IE) | 2022-05-26 | — | — | US | claimed |
| EP-3947744-A1 | METHODS OF DIAGNOSING DISEASE | 4D Pharma Cork Limited (IE) | 2022-02-09 | — | — | EP | claimed |
| US-20160089464-A1 | MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY | 2016-03-31 | — | — | US | claimed |
| EP-2723315-A2 | USE OF SILICONE ELASTOMERS IN COSMETIC PREPARATIONS | Beiersdorf AG (DE) | 2014-04-30 | — | — | EP | claimed |
| CN-103319521-A | Cyclic siloxane compositions for the release of active ingredients | GEN ELECTRIC | 2013-09-25 | — | — | CN | claimed |
| CN-103296220-A | Series-connection-type organic electroluminescence module | INNOCOM TECH SHENZHEN LTD | 2013-09-11 | — | — | CN | claimed |
| WO-2013000742-A2 | USE OF SILICONE ELASTOMERS IN COSMETIC PREPARATIONS | BEIERSDORF AG (DE) | 2013-01-03 | — | — | WO | claimed |
| US-20060292188-A1 | Ophthalmic solution with a flavoring agent | BAUSCH & LOMB INCORPORATED | 2006-12-28 | — | — | US | claimed |
| WO-2006132870-A1 | OPHTHALMIC SOLUTION WITH A FLAVORING AGENT | BAUSCH & LOMB INCORPORATED (US) | 2006-12-14 | — | — | WO | claimed |
| US-6867023-B2 | Production method of polyhydroxyalkanoate from substituted fatty acid ester as raw material | CANON KABUSHIKI KAISHA (JP) | 2005-03-15 | — | — | US | claimed |
| US-20020081646-A1 | Production method of polyhydroxyalkanoate form substituted fatty acid ester as raw material | CANON KABUSHIKI KAISHA (JP) | 2002-06-27 | — | — | US | claimed |
| EP-1201763-A2 | Production method of polyhydroxyalkanoate from substituted fatty acid ester as raw material | CANON KABUSHIKI KAISHA (JP) | 2002-05-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060292188-A1 | Ophthalmic solution with a flavoring agent | TAS2R60, TAS2R10, TAS2R40 | MAPT 678/4885RXFP1 689/4885HDAC1 2401/4885 |
| US-20020081646-A1 | Production method of polyhydroxyalkanoate form substituted fatty acid ester as raw material | FASN, FFAR1, ACADM | MAPT 4818/4885RXFP1 1524/4885HDAC1 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.